Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.
复制标题
DOI：
10.1038/sj.bjc.6602922
复制
发表时间：
2006-01-30
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
转移性乳腺癌患者的预后预测仍然存在问题。本研究评价了基于炎症的评分（格拉斯哥预后评分，GPS）在转移性乳腺癌患者中的价值。GPS的构建如下：C反应蛋白升高（>10 mg l−1）和低白蛋白血症（<35 g l−1）的患者被分配为2分。仅存在一种或不存在这些生化异常的患者的评分分别为1或0。共研究了96例患者。在随访期间，51名患者死于癌症。在GPS和接受治疗的多变量分析中，只有GPS（HR 2.26，95% CI 1.45-3.52，P<0.001）与癌症特异性生存率显著相关。全身炎症反应（GPS）的存在似乎是转移性乳腺癌患者预后不良的一个有用指标，与治疗无关。
Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as follows: patients with both an elevated C-reactive protein (>10 mg l−1) and hypoalbuminaemia (<35 g l−1) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. In total, 96 patients were studied. During follow-up 51 patients died of their cancer. On multivariate analysis of the GPS and treatment received, only the GPS (HR 2.26, 95% CI 1.45–3.52, P<0.001) remained significantly associated with cancer-specific survival. The presence of a systemic inflammatory response (the GPS) appears to be a useful indicator of poor outcome independent of treatment in patients with metastatic breast cancer.
登录
查看更多内容
影响因子：
4.7
作者：
Mahmoud, Fade Aziz;Rivera, Nilo I
通讯作者：
Rivera, Nilo I
影响因子：
8.8
作者：
通讯作者：
--
DOI：
10.1097/01.blo.0000092981.12414.7b
发表时间：
2003-10-01
影响因子：
4.2
作者：
Ali, SM;Harvey, HA;Lipton, A
通讯作者：
Lipton, A
影响因子：
3.8
作者：
Insa, A;Lluch, A;Garcia-Conde, J
通讯作者：
Garcia-Conde, J
影响因子：
2.9
作者：
O'Gorman, P;McMillan, DC;McArdle, CS
通讯作者：
McArdle, CS